Scholar Rock files for IPO

Scholar Rock Holding Corp. (Cambridge, Mass.) proposed to raise up to $75 million in an IPO on NASDAQ underwritten by Jefferies, Cowen, BMO Capital Markets and Wedbush PacGrow.

Scholar Rock is developing a pipeline of candidates based on its growth factor modulation platform. It expects to begin Phase I testing this quarter of lead candidate SRK-015, an inhibitor of latent myostatin (MSTN; GDF8) activation, to treat spinal muscular atrophy (SMA), for which it has Orphan Drug designation. The company has other preclinical programs for immuno-oncology, fibrosis and anemia...